Logo
x

Search

Subscribe Now

Mavacamten

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

  • March 11, 2021
LianBio Reports the NMPA Acceptance of NDA and Granted Priority Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy

    LianBio Reports the NMPA Acceptance of NDA and Granted Priority Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy

    • April 24, 2023
    BMS’ Camzyos (mavacamten) Receives the US FDA’s Approval for the Treatment of Symptomatic New York Heart Association Class II-III Obstructive HCM

      BMS’ Camzyos (mavacamten) Receives the US FDA’s Approval for the Treatment of Symptomatic New York Heart Association Class II-III...

      • April 29, 2022
      BMS Presents Results of Mavacamten in (EXPLORER-LTE) Cohort of the (MAVA-LTE) Study for Symptomatic Obstructive Hypertrophic Cardiomyopathy at ACC 2022

        BMS Presents Results of Mavacamten in (EXPLORER-LTE) Cohort of the (MAVA-LTE) Study for Symptomatic Obstructive Hypertrophic Cardi...

        • April 4, 2022
        BMS Reports Results of Mavacamten in P-III (VALOR-HCM) Study for the Treatment of Obstructive Hypertrophic Cardiomyopathy

          BMS Reports Results of Mavacamten in P-III (VALOR-HCM) Study for the Treatment of Obstructive Hypertrophic Cardiomyopathy

          • February 17, 2022
          Insights+: Breakthrough Therapy Designation by the US FDA in 2020

            Insights+: Breakthrough Therapy Designation by the US FDA in 2020

            • March 11, 2021
            Image

            Incisive News in 3 Shots.

            Contact Us

            Our Information

            Follow Us

            Copyright © 2025 PharmaShots - All Rights Reserved.